Evolocumab Shows Sustained Cardiovascular Benefits in Older Patients With ASCVD: FOURIER Trial Findings Medha Baranwal10 Feb 2025 9:15 AM ISTUSA: A recent study has highlighted the long-term benefits of evolocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in older...
Lerodalcibep Matches Evolocumab in LDL-C Reduction for HoFH: Lancet Dr. Shravani Dali1 Feb 2025 8:45 AM ISTResearchers have found in Phase 3 LIBerate-HoFH trial that Lerodalcibep, a third-generation PCSK9 inhibitor, showed similar efficacy to evolocumab in...
PCSK9 Inhibitors and Statins for lowering LDL Cholesterol Levels exhibit Long-Term Cognitive Safety: Study Dr.Niharika Harsha B28 Dec 2024 9:00 AM ISTA recent groundbreaking study published in the journal NEJM Evidence found no association between exposure to very low cholesterol levels achieved...
Evolocumab reduces major adverse cardiovascular events in patients with and without multivessel disease: FOURIER Medha Baranwal14 Feb 2024 10:30 AM ISTUSA: The PCSK9 inhibitor evolocumab significantly reduces the rate of major adverse cardiovascular events (MACEs) in patients with and without...
Evolocumab has no negative impact on cognitive function among paediatric patients with FH Aditi8 Nov 2023 3:00 AM ISTPCSK9 inhibition with evolocumab reduces low-density lipoprotein cholesterol in adults and children with familial hypercholesterolaemia (FH). The...
Adding lipid-lowering therapies to statin therapy help to achieve low-LDL cholesterol goals Dr. Kamal Kant Kohli30 Dec 2022 10:15 AM ISTUSA: When combined with maximally tolerated statins to reduce LDL-C, non-high-density lipoprotein cholesterol, and apolipoprotein B levels and make it...
Evolocumab addition to statins fails to prevent microvascular dysfunction in patients undergoing PCI Aditi14 Dec 2022 11:00 AM ISTJAPAN: A recently completed study of coronary intervention published in EuroIntervention has highlighted the outcome of Evolocumab pretreatment...
Long-term use of evolocumab tied to sustained reduction of LDL C and CV events: FOURIER-OLE trial Dr. Kamal Kant Kohli3 Sept 2022 11:00 AM ISTEvolocumab is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor used to lower CVD risk by controlling LDL cholesterol.According to...
Evolocumab Improves Features Of Plaque Stability In patients of ACS: HUYGENS trial Medical Dialogues Bureau30 Aug 2021 6:15 AM ISTUSA: Repatha (evolocumab) in addition to optimized statin therapy, in comparison with optimized statin therapy alone, significantly improved features...
PCSK9 inhibitors may slow progression of aortic stenosis Dr. Kamal Kant Kohli1 May 2020 11:33 AM ISTEvolocumab (Repatha) decreases LDL cholesterol and has significant impact on Myocardial infarction type and size. Researchers in an additional...
Evolocumab effectively lowers LDL-C in familial hypercholesterolemia patients: JACC Medha Baranwal18 Jan 2020 10:00 AM ISTDelhi: Evolocumab (Repatha) is safe and effective for the treatment of familial hypercholesterolemia (FH), a recent study in the Journal of the...
5 important trials in Preventive Cardiology that came in 2015 Dr. Manav Aggarwal30 Dec 2015 10:47 AM ISTThe field of preventive cardiology say some major developments and researches coming out in the year 2015.Here are a few important trials that came in...
